Neo Ivy Capital Management Purchases Shares of 93,260 The Chemours Company $CC

Neo Ivy Capital Management acquired a new position in shares of The Chemours Company (NYSE:CC) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 93,260 shares of the specialty chemicals company’s stock, valued at approximately $1,477,000.

Other hedge funds have also modified their holdings of the company. MTM Investment Management LLC acquired a new stake in shares of Chemours during the second quarter worth $27,000. Evelyn Partners Asset Management Ltd acquired a new position in shares of Chemours in the 2nd quarter valued at $37,000. Hantz Financial Services Inc. boosted its position in shares of Chemours by 334.2% in the 3rd quarter. Hantz Financial Services Inc. now owns 4,329 shares of the specialty chemicals company’s stock valued at $69,000 after purchasing an additional 3,332 shares during the period. Itau Unibanco Holding S.A. increased its stake in Chemours by 102.3% in the 2nd quarter. Itau Unibanco Holding S.A. now owns 7,149 shares of the specialty chemicals company’s stock worth $82,000 after purchasing an additional 3,615 shares in the last quarter. Finally, CWM LLC raised its holdings in Chemours by 32.4% during the 3rd quarter. CWM LLC now owns 5,682 shares of the specialty chemicals company’s stock worth $90,000 after buying an additional 1,392 shares during the period. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Mizuho raised its price target on Chemours to $21.00 and maintained an “outperform” rating, signaling analyst confidence in upside potential versus the current price. Benzinga Coverage
• Neutral Sentiment: Zacks Research published a FY2028 EPS projection of $2.50 for Chemours — a longer-term estimate that could be constructive if later quarters show recovery, but it comes alongside multiple near-term downgrades. MarketBeat: CC
• Negative Sentiment: Zacks cut several near-term earnings forecasts across 2026–2027: Q1 2026 to ($0.09) from $0.20, Q2 2026 to $0.60 from $0.69, Q3 2026 to $0.42 from $0.57, Q4 2026 to $0.13 from $0.29, FY2026 to $1.06 from $1.75, and FY2027 to $1.97 from $2.30. These downward revisions signal weaker expected near-term profitability and are likely weighing on the stock. MarketBeat: Zacks Revisions
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Chemours, which introduces legal/settlement risk and can increase volatility and investor concern until clarity emerges. PR Newswire: Pomerantz Investigation

Chemours Trading Down 1.9%

NYSE:CC opened at $16.44 on Friday. The company has a debt-to-equity ratio of 16.33, a current ratio of 1.78 and a quick ratio of 0.85. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $21.85. The stock’s 50-day moving average is $16.38 and its two-hundred day moving average is $14.74. The stock has a market cap of $2.47 billion, a PE ratio of -6.63 and a beta of 1.60.

Chemours (NYSE:CC) last issued its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. Chemours had a positive return on equity of 41.75% and a negative net margin of 6.41%.The firm’s quarterly revenue was down 2.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.09 EPS. As a group, equities research analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Friday, February 27th will be given a $0.0875 dividend. The ex-dividend date is Friday, February 27th. This represents a $0.35 dividend on an annualized basis and a yield of 2.1%. Chemours’s dividend payout ratio is presently -14.11%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $17.00 price objective on shares of Chemours in a research note on Monday, February 23rd. Morgan Stanley lifted their target price on shares of Chemours from $15.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, February 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $18.00 price target on shares of Chemours in a report on Friday, January 16th. The Goldman Sachs Group raised their price objective on shares of Chemours from $14.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Truist Financial lifted their price objective on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Chemours currently has a consensus rating of “Hold” and a consensus price target of $18.40.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.